China-based Eminence Biotechnology (Suzhou) Co., Ltd. has announced the full operation of its state-of-the-art cell culture media facility, which will cater to the production of vaccines, gene therapies, cell therapies, antibodies, and recombinant proteins. The new facility, located at the BIOBAY Phase II in Suzhou Industrial Park, spans approximately 7,000 square meters and includes dedicated zones for media production, warehousing, and laboratory functions.
Enhanced Production Capacity and Advanced Technology
Equipped with three dry powder production lines and two liquid production lines, the facility has an annual output capacity of up to 20 million liters of dry powder media and 300,000 liters of liquid media. This expansion comes after over seven years of growth for the company’s factory in Changzhou, which has reached its capacity. The new facility in Suzhou was designed to leverage the operational experience from Changzhou and integrate it with more advanced large-scale pin-milling technology, standardizing production processes and ensuring stable and continuous production.
Strategic Integration and Operational Efficiency
The integration of advanced technology with operational expertise from Changzhou positions Eminence Biotechnology to meet the growing demand for cell culture media in the biopharmaceutical industry. The new facility’s capacity and technological capabilities will support the company’s commitment to providing high-quality media solutions for a range of applications, from vaccine development to gene and cell therapies.-Fineline Info & Tech
